Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.

@article{Rao2008SafetyEA,
  title={Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.},
  author={Aarati Rao and Michael Kelly and Mark Musselman and Jagadeesh Ramadas and David A. H. Wilson and William F Grossman and Shalini Shenoy},
  journal={Pediatric blood & cancer},
  year={2008},
  volume={50 4},
  pages={822-5}
}
BACKGROUND Autoimmune hematologic cytopenias in children often require therapeutic intervention. We report a prospective pediatric multicenter trial of rituximab for refractory or steroid-dependent patients. METHODS Four doses of rituximab (375 mg/m(2)/dose) were administered weekly. Patients without response after three doses were offered dose escalation to 750 mg/m(2)/dose/week x 3. Safety, efficacy, and immunologic tests were evaluated after therapy. RESULTS Twenty-nine of 30 children (2… CONTINUE READING